Anida Pharma is utilizing the potential of resolution biology to develop novel treatment paradigms to prevent and restore
WHO WE ARE
Anida is a preclinical-stage biopharmaceutical company leveraging the knowledge around the body’s own homeostatic and protective mechanisms to develop targeted therapeutics in the fields of vision, hearing and cognition. The combination of the unique discoveries in Dr. Charles Serhan’s Laboratory at Harvard Medical School with our team’s extensive drug development experience has enabled us to develop a pipeline of treatments that targets sensory organ dysfunction and with an initial focus on high unmet medical needs in pediatric patients:
Retinopathy of Prematurity;
Drug-induced hearing loss in cancer chemotherapy treated children;
Brain injury in the newborn;
and with the potential to serve broader adult and pediatric indication areas
The immune system is critical for an organism’s integrity and survival. However, an excessive immune response is associated with tissue death and dysfunctional repair, and may lead to chronic organ failure or even become deleterious. To prevent permanent loss of function the body has adopted highly specific counter-mechanisms, which if activated may offer unique therapeutic advantages. Anida’s drug in development, AP-001, is an endogenous lipid-derived agonistic small molecule from the DHA metabolome. AP-001 acts on several pathways to ensure system integrity (see figure). By independently regulating inflammation, cell death and tissue repair AP-001 addresses the need to control for the redundancy of pathological mechanisms associated with acute events. These may be an infection, trauma, or aberrant tissue response due to changed physiological conditions, and are further exemplified by Anida’s targeted treatment indications. AP-001 is in the scientific literature referred to as neuroprotectin D1 (NPD1) or protectin D1 (PD1).
Sensory Organ Exploratory Indications
With our commitment to addressing needs for the treatment and prevention of sensory organ dysfunction Anida is also using its
platform and knowledge base to explore a wider range of indications including age-related macular degeneration (AMD), other retinal
disorders, as well as adult and noise-induced sensorineural hearing loss, and certain neurodegenerative conditions.
Anida is working to address a range of potentially debilitating outcomes in infants and children due to premature birth, a complicated birth or complications due to life-saving cancer chemotherapy.
The further development of our programs will also benefit large adult patient populations.
SCIENTIFIC AND CLINICAL ADVISOR AND COLLABORATORS
Charles N. Serhan, PhD, DSc
Chair Anida Scientific Advisory Board
Director, Center for Experimental Therapeutics and Reperfusion Injury
Brigham and Women’s Hospital
The Simon Gelman Professor of Anaesthesia, Harvard Medical School
Anida Pharma Inc.
155 Brookline Street, Suite 005
Cambridge, MA 02139
Tel: 617 331 5033